OSI Pharmaceuticals Inc. (OSIP) said it now believes that the 2010 overall revenue percentage growth rate will be in the mid-teens and re-affirmed that adjusted earnings per share will grow at 10% or more. Analysts polled by Thomson Reuters expect the company to report earnings of $1.62 per share on revenues of $476.31 million for fiscal 2010. Analysts' estimates typically exclude special items.
The company also provided investors with an update on the re-purchase of a portion of its outstanding convertible debt bonds. As of December 22, 2009, the Company had purchased $39.5 million face value of the 2023 convertible bonds for $37.6 million and $40.0 million face value of the 2038 convertible bonds for $37.4 million. The aggregate amount of the Company's outstanding 2038 Notes, 2023 Notes and 2025 Notes at face value is now equal to $335.5 million. The company said that it may continue to selectively re-purchase convertible debt bonds and common stock throughout 2010.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.